la Porte Charles J L, Wasmuth Jan-Christian, Schneider Katrin, Rockstroh Jürgen K, Burger David M
Department of Clinical Pharmacy, University Medical Centre, Nijmegen, The Netherlands.
AIDS. 2003 Jul 25;17(11):1700-2. doi: 10.1097/00002030-200307250-00018.
Patients receiving a lopinavir/ritonavir and saquinavir dual protease inhibitor-based antiretroviral salvage regimen were studied to evaluate the pharmacokinetics, tolerability and efficacy of the regimen. Pharmacokinetic curves were obtained for lopinavir and saquinavir. Patient records were studied for adverse events and efficacy data. The pharmacokinetics of lopinavir and saquinavir were comparable with literature data, except for the saquinavir 0-12 h area under the curve and maximum concentration. The tolerability of the regimen was good and efficacy was encouraging.
对接受基于洛匹那韦/利托那韦和沙奎那韦的双蛋白酶抑制剂抗逆转录病毒挽救治疗方案的患者进行了研究，以评估该方案的药代动力学、耐受性和疗效。获得了洛匹那韦和沙奎那韦的药代动力学曲线。研究患者记录以获取不良事件和疗效数据。除沙奎那韦0至12小时曲线下面积和最大浓度外，洛匹那韦和沙奎那韦的药代动力学与文献数据相当。该方案耐受性良好，疗效令人鼓舞。
